ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00132379 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: ABR-217620
DRUG: docetaxel

Sponsor

Active Biotech AB